0243.KLSE Cengild Medical Berhad
- Market cap
- MYR 133M
- P/E
- 16.0x
- P/B
- 1.15x
- ROE
- 9.5%
- Dividend yield
- 4.37%
- Fundamental score
- 2.5/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 0243.KLSE undervalued?
Graham number0243.KLSE trades 9.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cengild Medical Berhad fundamental analysis
13 of 22 checks passedROE 0/2
Low return on equity (9.5%), below 10%.
ROA 1/1
Return on assets (5.1%) is above the industry median (-19.8%).
Profit Consistency 2/2
Profitable for 7 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (3.5%) is above the 5-year average (2.4% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (3.5%) is below the industry median (3.8%).
Revenue Growth 1/2
Revenue grew 1.4% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (69.6%), up to 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 1/1
EBIT is 75.3x against interest expense, well covered.
PE vs Market 0/1
PE (16.0x) is above the market median (11.4x).
PE vs Industry 1/1
PE (16.0x) is below the industry median (18.6x).
PBV 1/1
Price to book (1.1x) is below the industry median (3.1x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 18.3, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 6.76, above 1.
Dividend Yield 1/2
Dividend yield (4.4%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 51.0%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
About Cengild Medical Berhad
Cengild Medical Berhad, an investment holding company, operates a medical center in Malaysia. The company offers various care and treatment consultant services for gastrointestinal and liver diseases, morbid obesity, and oncology and urological conditions; general cardiology and gynecology assessment; gastroenterology and hepatology; anesthesiology, general surgery, internal medicine, and radiology; ear, nose and throat; gastrointestinal surgeries, including upper gastrointe…
Full company profileCengild Medical Berhad financial statements
Cengild Medical Berhad annual financial statements (MYR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 39.2M | 63.5M | 64.4M | 70.3M | 66.8M | 80.0M | 73.2M |
| Gross Profit | 17.5M | 26.7M | 26.1M | 30.7M | 31.1M | 36.9M | 34.6M |
| Operating Income | 7.12M | 14.7M | 13.0M | 14.5M | 13.2M | 19.0M | 14.1M |
| EBITDA | - | - | - | 21.3M | 21.3M | 24.9M | 19.8M |
| Net Income | 3.95M | 10.0M | 9.39M | 13.3M | 11.1M | 11.1M | 11.4M |
| EPS | 0.00 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 |
| Balance Sheet | |||||||
| Total Assets | 47.1M | 46.0M | 120M | 132M | 132M | 180M | 224M |
| Total Liabilities | 37.3M | 32.2M | 26.6M | 25.6M | 21.1M | 66.0M | 104M |
| Shareholders' Equity | 9.79M | 13.8M | 93.0M | 106M | 111M | 114M | 120M |
| Cash & Short-term Investments | 5.55M | 482K | 5.83M | 759K | 1.92M | 11.8M | 7.40M |
| Cash Flow | |||||||
| Operating Cash Flow | 11.2M | 14.3M | 14.1M | 13.8M | 12.9M | 16.1M | 13.1M |
| Capital Expenditure | 610K | 1.70M | 428K | 2.13M | 15.7M | 37.3M | 81.3M |
| Free Cash Flow | 10.6M | 12.6M | 13.6M | 11.8M | -2.80M | -21.2M | -68.2M |
| Ratios | |||||||
| ROE | 40.4% | 72.6% | 10.1% | 12.5% | 10.0% | 9.7% | 9.5% |
| ROA | 8.4% | 21.8% | 7.9% | 10.1% | 8.4% | 6.1% | 5.1% |
| Net Profit Margin | 10.1% | 15.8% | 14.6% | 18.9% | 16.6% | 13.8% | 15.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cengild Medical Berhad dividends
- Dividend yield
- 4.37%
- Forward dividend
- -
- Payout ratio
- 51.0%
- Ex-dividend date
- Sep 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | MYR 5.83M | 0.01 | 51.0% |
| 2025 | MYR 8.08M | 0.01 | 73.1% |
| 2024 | MYR 6.16M | 0.01 | 55.6% |
| 2023 | MYR 6.06M | 0.01 | 45.6% |
| 2022 | MYR 6.06M | 0.01 | 64.5% |
| 2021 | MYR 7.28M | 0.01 | 72.8% |
| 2020 | MYR 7.28M | 0.01 | 184.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Cengild Medical Berhad
- Insiders 69.69%
- Institutions 0.00%
- Public & others 30.31%
- Shares outstanding 833M
- Free float 252M
Cengild Medical Berhad company profile
- Company name
- Cengild Medical Berhad
- Ticker
- 0243.KLSE
- ISIN
- MYQ0243OO004
- Exchange
- Kuala Lumpur Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 151
- Fiscal year end
- June
- Address
- Nexus @ Bangsar South, Kuala Lumpur, Malaysia, 59200
- Phone
- 60 3 2242 7000
- Website
- cengild.com
About Cengild Medical Berhad
Cengild Medical Berhad, an investment holding company, operates a medical center in Malaysia. The company offers various care and treatment consultant services for gastrointestinal and liver diseases, morbid obesity, and oncology and urological conditions; general cardiology and gynecology assessment; gastroenterology and hepatology; anesthesiology, general surgery, internal medicine, and radiology; ear, nose and throat; gastrointestinal surgeries, including upper gastrointestinal, hepatobiliary, pancreatic, colorectal surgery, and bariatric surgery; and chemotherapy. It also provides medical management services; nursing services and clinical support services; clinical laboratory and pharmacy; operating theatre, endoscopy, radiology and imaging services; accident and emergency care, and health screenings; and consultant services. Cengild Medical Berhad was founded in 2017 and is based in Kuala Lumpur, Malaysia.
Cengild Medical Berhad management
10- Dr. Huck Joo TanExecutive Chairman & Medical Director · born 1968
- Dr. Mohamed Akhtar Bin Mohamed Ditali QureshiHead of Medical Adv. Board and Operating Theatre & Central Sterile Supply Dept. and Exec. Director · born 1961
- Ms. Wai Fern LeeGroup Chief Executive Officer · born 1975
- Ms. Suik Hae WongChief Financial Officer · born 1982
- Dr. Siew Kuen OngHead of Department, Medicine & Endoscopy · born 1967
- Dr. Ramesh K. GurunathanHead of Department for General Surgery & Upper GIT · born 1966
- Dr. Mustafa Mohammed TaherHead of Outpatient Department · born 1977
- Ms. Lay Kim ChongCompany Secretary
- Mr. Thiam Chai Tee MAICSACompany Secretary
- Ms. Siew Yeen Wong MAISCACompany Secretary · born 1970